

RECEIVED  
CENTRAL FAX CENTER

NOV 05 2003

OFFICIAL

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Hans Josef Stauss and Liquan Gao

Serial No.: 09/625,963

Art Unit: 1644

Filed: July 26, 2000

Examiner: A. Decloux

For: "IMMUNOTHERAPEUTIC METHODS USING EPITOPES OF WT-1 AND GATA-1"

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §1.56 and 37 C.F.R. §1.97, Applicants submit a Supplemental Information Disclosure Statement, including four (4) pages of Form PTO-1449. We were unable to locate copies of those references indicated with an asterisk (\*). We will forward copies of these shortly.

It is believed that no fee is required with this submission. However, should a fee be required, the Commissioner is hereby authorized to charge any fees to Deposit Account No. 50-1868.

**Publications**

\*ALGAR, et al., "A WT1 antisense oligonucleotide inhibits proliferation and induces apoptosis in myeloid leukemia cell lines," *Oncogene* 12: 1005-1014 (1996).

\*BAIRD, et al., "Expression of the Wilms' tumor gene (WT1) in normal hemopoiesis," *Exp. Hematol.* 25: 312-320 (1997).

U.S.S.N.: 09/625,963  
Filed: July 26, 2000  
SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

\*BHATIA, et al., "A newly discovered class of human hematopoietic cells with SCID-repopulating activity," *Nature Med.* 4: 1038-1045 (1998).

\*BONNET & DICK, "Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell," *Nature Med.* 3: 730-737 (1997).

\*BOSE, et al., "The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease," *Blood* 92: 3362-3367 (1998).

\*CAMPBELL, et al., "Constitutive expression of the Wilms tumor suppressor gene (WT1) in renal cell carcinoma," *Int. J. Cancer* 78: 182-188 (1998).

\*DAZZI & GOLDMAN, "Adoptive immunotherapy following allogeneic bone marrow transplantation," *Ann. Rev. Med.* 49: 329-340 (1998).

\*DAZZI, et al., "The kinetics and extent of engraftment of chronic myelogenous leukemia cells in non-obese diabetic/severe combined immunodeficiency mice reflect the phase of the donor's disease: an in vitro model of chronic myelogenous leukemia biology," *Blood* 92: 1390-1396 (1998).

\*DEMARS, et al., "Homozygous deletion that simultaneously eliminate expression of class I and class II antigens of EBV-transformed B-lymphoblastoid cells. I. Reduced proliferative responses of autologous and allogeneic T cells to mutant cells that have decreased expression of class II antigens," *Hum. Immunol.* 11: 77-97 (1984).

\*DEN HAAN, et al., "The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism," *Science* 279: 1054-1057 (1998).

\*DIGIUSTO, et al., "Human fetal bone marrow early progenitors for T, B, and myeloid cells are found exclusively in the population expressing high levels of CD34," *Blood* 84: 421-432 (1994).

\*FINDLEY, JR., et al., "Two new acute lymphoblastic leukemia cell lines with early B-cell phenotypes," *Blood* 60: 1305-1309 (1982).

\*GRIFFIN, et al., "Clonogenic cells in acute myeloblastic leukemia," *Blood* 68: 1185-1195 (1986).

\*INOUE, et al., "Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia," *Blood* 89: 1405-1412 (1997).

\*INOUE, et al., "Wilms' tumor gene (WT1) competes with differentiation-inducing signal in hematopoietic progenitor cells," *Blood* 91: 2969-2976 (1998).

U.S.S.N.: 09/625,963  
Filed: July 26, 2000  
SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

\*INOUE, et al., "WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia," *Blood* 84: 3071-3079 (1994).

\*KOLB, et al., "Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients," *Blood* 76: 2462-2465 (1990).

\*LOZZIO & LOZZIO, "Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome," *Blood* 45: 321-334 (1975).

\*MAURER, et al., "The Wilms' tumor gene is expressed in a subset of CD34+ progenitors and downregulated early in the course of differentiation *in vitro*," *Exp. Hematol.* 25: 945-950 (1997).

\*MCCULLOCH, "Stem cells in normal and leukemic hemopoiesis," *Blood* 62: 1-13 (1983).

\*MENKE, et al., "The Wilms' tumor 1 gene: oncogene or tumor suppressor gene?" *Int. Rev. Cytol.* 181: 151-212 (1998).

\*MOLLDREM, et al., "Cytotoxic T-lymphocytes specific for a nonpolymorphic proteinase-3 peptide preferentially inhibit chronic myeloid-leukemia colony-forming units," *Blood* 90: 2529-2534 (1997).

\*O'BRIEN & GOLDMAN, "Current approaches to hematopoietic stem-cell purging in chronic myeloid leukemia," *J. Clin. Oncol.* 13: 541-546 (1995).

\*OSAKA, et al., "WT1 contributes to leukemogenesis: expression patterns in 7,12-dimethylbenz[a]anthracene (DMBA)-induced leukemia," *Int. J. Cancer* 72: 696-699 (1997).

\*PEGORARO, et al., "Establishment of a Ph1-positive human cell line (BV173)," *J. Natl. Cancer. Inst.* 70: 447-453 (1983).

\*PETERSDORF, et al., "Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient," *Blood* 92: 3515-3520 (1998).

\*RODECK, et al., "Expression of the wt1 Wilms' tumor gene by normal and malignant human melanocytes," *Int. J. Cancer* 59: 78-82 (1994).

\*SADOVNIKA, et al., "Generation of human tumor-reactive cytotoxic T cells against peptides presented by non-self HLA class I molecules," *Eur. J. Immunol.* 28: 193-200 (1998).

\*SILBERSTEIN, et al., "Altered expression of the WT1 Wilms tumor suppressor gene in human breast cancer," *Proc. Natl. Acad. Sci. USA* 94: 8132-8137 (1997).

U.S.S.N.: 09/625,963  
Filed: July 26, 2000  
SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

\*SIMPSON, et al., "Much ado about minor histocompatibility antigens," *Immunol. Today* 19: 108-112 (1998).

\*SMIT, et al., "T cells recognizing leukemic CD34(+) progenitor cells mediate the antileukemic effect of donor lymphocyte infusions for relapsed chronic myeloid leukemia after allogenic stem cell transplantation," *Proc. Natl. Acad. Sci USA* 95: 10152-10157 (1998).

\*STRAUSS, "Immunotherapy with CTL restricted by non-self MHC," *Immunol. Today* 20: 180-183 (1999).

\*SVEDBERG, et al., "Constitutive expression of the Wilms' tumor gene (WT1) in the leukemic cell line U937 blocks part of the differentiation program," *Oncogene* 16: 925-932 (1998).

\*VIEL, et al., "Molecular mechanisms possibly affecting WT1 function in human ovarian tumors," *Int. J. Cancer* 57: 515-521 (1994).

\*WANG, et al., "High level engraftment of NOD/SCID mice by primitive normal and leukemic hematopoietic cells from patients with chronic myeloid leukemia in chronic phase," *Blood* 91: 2406-2414 (1998).

\*WARREN, et al., "Minor histocompatibility antigens as targets for T-cell therapy after bone marrow transplantation," *Curr. Opin. Hematol.* 5: 429-433 (1998).

\*YAMAGAMI, et al., "Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis," *Blood* 87: 2878-2884 (1996).


\*ZEMMOUR, et al., "The HLA-A,B 'negative' mutant cell line C1R expresses a novel HLA-B35 allele which also has a point mutation in the translation initiation codon," *J. Immunol.* 148: 1941-1948 (1992).

U.S.S.N.: 09/625,963  
Filed: July 26, 2000  
SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT

**Certificate of Facsimile Transmission**

I hereby certify that this Supplemental Information Disclosure Statement, along with any paper referred to as being attached or enclosed are being facsimile transmitted on this date, November 5, 2003, to the Commissioner for Patents, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: November 5, 2003

  
Peggy Bailey

# 607118\_v1

Please type a plus sign (+) inside this box →



PTO/S&T/BA 110-98  
Approved for use through 10/31/99. OMB 0951-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Complete if Known	
		Application Number	09/625,963
Sheet 1 of 4		Filing Date	July 28, 2000
		First Named Inventor	Hans Josef Stauss
		Group Art Unit	1644
		Examiner Name	A. Decloux
		Attorney Docket Number	ICI 101

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		ALGAR, et al., "A WT1 antisense oligonucleotide inhibits proliferation and induces apoptosis in myeloid leukemia cell lines," <i>Oncogene</i> 12: 1005-1014 (1996).	
		BAIRD, et al., "Expression of the Wilms' tumor gene (WT1) in normal hemopoiesis," <i>Exp. Hematol.</i> 25: 312-320 (1997).	
		BHATIA, et al., "A newly discovered class of human hematopoietic cells with SCID-repopulating activity," <i>Nature Med.</i> 4: 1038-1045 (1998).	
		BONNET & DICK, "Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell," <i>Nature Med.</i> 3: 730-737 (1997).	
		BOSE, et al., "The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease," <i>Blood</i> 92: 3362-3367 (1998).	
		CAMPBELL, et al., "Constitutive expression of the Wilms tumor suppressor gene (WT1) in renal cell carcinoma," <i>Int. J. Cancer</i> 78: 182-188 (1998).	
		DAZZI & GOLDMAN, "Adoptive immunotherapy following allogeneic bone marrow transplantation," <i>Ann. Rev. Med.</i> 49: 329-340 (1998).	
		DAZZI, et al., "The kinetics and extent of engraftment of chronic myelogenous leukemia cells in non-obese diabetic/severe combined immunodeficiency mice reflect the phase of the donor's disease: an in vitro model of chronic myelogenous leukemia biology," <i>Blood</i> 92: 1390-1396 (1998).	
		DEMARS, et al., "Homozygous deletion that simultaneously eliminates expression of class I and class II antigens of EBV-transformed B-lymphoblastoid cells. I. Reduced proliferative responses of autologous and allogeneic T cells to mutant cells that have decreased expression of class II antigens," <i>Hum. Immunol.</i> 11: 77-97 (1984).	
		DEN HAAN, et al., "The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism," <i>Science</i> 279: 1054-1057 (1998).	

Examiner's Signature	Date Considered
----------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/BA (10-98)  
Approved for use through 10/31/99. OMB 0951-0031  
Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete If Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/625,963
		Filing Date	July 26, 2000
		First Named Inventor	Hans Josef Steuss
		Group Art Unit	1644
		Examiner Name	A. Decloux
Sheet	2	of	4
		Attorney Docket Number	ICI 101

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		DIGIUSTO, et al., "Human fetal bone marrow early progenitors for T, B, and myeloid cells are found exclusively in the population expressing high levels of CD34," Blood 84: 421-432 (1994).	
		FINDLEY, JR., et al., "Two new acute lymphoblastic leukemia cell lines with early B-cell phenotypes," Blood 60: 1305-1309 (1982).	
		GRIFFIN, et al., "Clonogenic cells in acute myeloblastic leukemia," Blood 68: 1185-1195 (1986).	
		INOUE, et al., "Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia," Blood 89: 1405-1412 (1997).	
		INOUE, et al., "Wilms' tumor gene (WT1) competes with differentiation-inducing signal in hematopoietic progenitor cells," Blood 91: 2969-2976 (1998).	
		INOUE, et al., "WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia," Blood 84: 3071-3079 (1994).	
		KOLB, et al., "Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients," Blood 76: 2462-2465 (1990).	
		LOZZIO & LOZZIO, "Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome," Blood 46: 321-334 (1975).	
		MAURER, et al., "The Wilms' tumor gene is expressed in a subset of CD34+ progenitors and downregulated early in the course of differentiation in vitro," Exp. Hematol. 25: 945-950 (1997).	
		MCCULLOCH, "Stem cells in normal and leukemic hemopoiesis," Blood 62: 1-13 (1983).	

Examiner's Signature	Date Considered
----------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-99)  
Approved for use through 10/31/99. OMB 0951-0001  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1996, no persons are required to respond to a collection of information unless it carries a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/625,963
		Filing Date	July 26, 2000
		First Named Inventor	Hans Josef Stauss
		Group Art Unit	1644
		Examiner Name	A. Decloux
		Attorney Docket Number	ICI 101
Sheet	3	of	4

OTHER ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		MENKE, et al., "The Wilms' tumor 1 gene: oncogene or tumor suppressor gene?" Int. Rev. Cytol. 181: 151-212 (1998).	
		MOLLOREM, et al., "Cytotoxic T-lymphocytes specific for a nonpolymorphic proteinase-3 peptide preferentially inhibit chronic myeloid-leukemia colony-forming units," Blood 90: 2529-2534 (1997).	
		O'BRIEN & GOLDMAN, "Current approaches to hematopoietic stem-cell purging in chronic myeloid leukemia," J. Clin. Oncol. 13: 541-546 (1995).	
		OSAKA, et al., "WT1 contributes to leukemogenesis: expression patterns in 7,12-dimethylbenz[a]anthracene (DMBA)-induced leukemia," Int. J. Cancer 72: 696-699 (1997).	
		PEGORARO, et al., "Establishment of a Ph1-positive human cell line (BV173)," J. Natl. Cancer. Inst. 70: 447-453 (1983).	
		PETERSDORF, et al., "Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient," Blood 92: 3515-3520 (1998).	
		RODECK, et al., "Expression of the wt1 Wilms' tumor gene by normal and malignant human melanocytes," Int. J. Cancer 59: 78-82 (1994).	
		SADOVNIKA, et al., "Generation of human tumor-reactive cytotoxic T cells against peptides presented by non-self HLA class I molecules," Eur. J. Immunol. 28: 193-200 (1998).	
		SILBERSTEIN, et al., "Altered expression of the WT1 Wilms tumor suppressor gene in human breast cancer," Proc. Natl. Acad. Sci. USA 94: 8132-8137 (1997).	
		SIMPSON, et al., "Much ado about minor histocompatibility antigens," Immunol. Today 19: 108-112 (1998).	

Examiner's Signature	Date Considered
----------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 15 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box →



PTO/SB/08A (10-99)  
Approved for use through 10/31/00. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/625,963
		Filing Date	July 26, 2000
		First Named Inventor	Hans Josef Stauss
		Group Art Unit	1644
		Examiner Name	A. Decloux
		Attorney Docket Number	ICI 101
Sheet	4 of 4		

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		SMIT, et al., "T cells recognizing leukemic CD34(+) progenitor cells mediate the antileukemic affect of donor lymphocyte infusions for relapsed chronic myeloid leukemia after allogenic stem cell transplantation," Proc. Natl. Acad. Sci USA 95: 10152-10157 (1998).	
		STRAUSS, "Immunotherapy with CTL restricted by non-self MHC," Immunol. Today 20: 180-183 (1999).	
		SVEDBERG, et al., "Constitutive expression of the Wilms' tumor gene (WT1) in the leukemic cell line U937 blocks part of the differentiation program," Oncogene 16: 925-932 (1998).	
		VIEL, et al., "Molecular mechanisms possibly affecting WT1 function in human ovarian tumors," Int. J. Cancer 57: 615-621 (1994).	
		WANG, et al., "High level engraftment of NOD/SCID mice by primitive normal and leukemic hematopoietic cells from patients with chronic myeloid leukemia in chronic phase," Blood 91: 2406-2414 (1998).	
		WARREN, et al., "Minor histocompatibility antigens as targets for T-cell therapy after bone marrow transplantation," Curr. Opin. Hematol. 5: 429-433 (1998).	
		YAMAGAMI, et al., "Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis," Blood 87: 2878-2884 (1996).	
		ZEMMOUR, et al., "The HLA-A,B 'negative' mutant cell line C1R expresses a novel HLA-B35 allele which also has a point mutation in the translation initiation codon," J. Immunol. 148: 1941-1948 (1992).	

Examiner's Signature	Date Considered
----------------------	-----------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 10 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.